Merck & Co., Inc.

Merck’s research pipeline continues to grow as we accelerate our discovery efforts. In the past year, we have advanced 26 candidates to the next clinical development stage. We currently have seven candidates in Phase III development, 17 distinct candidates in Phase II and another 23 in Phase I.

A Robust Pipeline

Updated February 15, 2008

Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations.

  • Recent Advance Advanced Since February 2007
  • † Clinical program conducted by Allergan, Inc.
  • * Proof-of-Concept Molecule

  1. Phase III (2)

    1. Atherosclerosis, MK-0524B
    2. Cancer, MK-8669
      (deforolimus)
    3. Heart Failure, MK-7418
      (rolofylline)
    4. Hepatitis B Vaccine, V270
    5. Migraine, MK-0974
    6. Obesity, MK-0364
      (taranabant)
    7. Osteoporosis, MK-0822
      (odanacatib)

  2. Under FDA Review

    1. Atherosclerosis, MK-0524A
      Cordaptive (pending trademark)

  3. 2007 U.S. Approvals

    1. Diabetes
      Janumet
    2. HIV, MK-0518
      Isentress

  4. 2008 U.S. Approvals

    1. CINV, MK-0517
      Emend for Injection

(2) Candidates shown in Phase III include specific candidates.

 Copyright © 2009-2010 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.  Privacy  Terms of Use  Sitemap